FDA To Weigh Proposals For Lightened Hearing-Aid Regs
This article was originally published in The Gray Sheet
Following a White House report arguing that the current regulation of hearing aids is stifling innovation and raising costs, FDA has scheduled a gathering to discuss the future of hearing aid regulations. The agency has also reopened a comment period on a pending draft guidance. An industry trade group, however, is skeptical of proposals that have been put forward.
You may also be interested in...
Physicians and manufacturers alike expressed serious concerns with a proposal from White House advisors to make some hearing aids available over-the-counter and exempt from the Quality System Regulation at a recent FDA workshop. They argue the plan could endanger consumers without significantly lowering device costs.
Companies and consumer groups asked FDA for a clearer distinction between hearing aid devices and personal sound amplification products in recent comments submitted in response to an FDA draft guidance.
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”